Sedia Biosciences Corporation Assays - Notice of Intent for Sole Source Award

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order to Sedia Biosciences Corporation of Portland, OR, for Asante HIV-1 Rapid Recency Assays and HIV-1 LAg-Avidity EIA Avidity Kits. The assays and kits required are provided only by this company and are used in an ongoing HIV surveillance  program. This contract action is for supplies for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) (SAP) and 10 U.S.C. 2304(c)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals.

This notice of intent is not a request for competitive quotations.  Any interested companies are welcome to submit their ability to provide the specified products within three (3) days of the issuance of this notice.  A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government.  Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.  Any quotation/response should be emailed to contract specialist at emickle@cdc.gov by COB after three (3) business days from date of posting.